Regeneron Pharmaceuticals, Inc. (REGN)

Last Price$700.30.6%

Market Cap$75.4B

LTM Net Debt

($15.9B)

YoY Growth

+95.6%

3Y CAGR

+20.5%

5Y CAGR

+22.6%

Stock quality & Intrinsic value

7/10

39.9% undervalued

Start beating the S&P 500

Regeneron Pharmaceuticals, Inc. Net Debt

Annual

Quarterly

LTM

Crunching data... Almost there!

	Dec'05	Dec'06	Dec'07	Dec'08	Dec'09	Dec'10	Dec'11	Dec'12	Dec'13	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24
Net Debt	($98.5M)	($259.3M)	($566.5M)	($469.7M)	($232.3M)	($512.1M)	($91.4M)	($128.8M)	($577.4M)	($902.9M)	($1,314.5M)	($1,421.8M)	($2,192.6M)	($3,856.4M)	($5,757.2M)	($4,026.9M)	($9,113.3M)	($11.6B)	($8,141.9M)	($6,308.1M)

REGN

Key metrics and insights to make informed decisions.

View full analysis

Overvalued or undervalued?

Check the intrinsic value for REGN and see if it's the right time to invest.

Dive in

Regeneron Pharmaceuticals, Inc. (REGN) Net Debt comparison analysis

Crunching data... Almost there!

REGN key stats

USD

Millions

Billions

Annual

Quarterly

Trailing

Key stats

Income statement

Balance sheet

Cash Flow Statement

Valuation

Ratios

Per share

Per employee

Dividends & Yields

Crunching data... Almost there!

Discover more Stock Ideas

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%

S&P Outperformance 19.1%

Next 3M Predicted Return 20.3%

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%

S&P Outperformance 22.3%

Next 3M Predicted Return 26.8%

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.

3M Return 28.4%

S&P Outperformance 15.4%

Next 3M Predicted Return 16.9%

More ideas -->

FAQ

1) What is Regeneron Pharmaceuticals, Inc.'s Net Debt?

As of today, Regeneron Pharmaceuticals, Inc.'s last 12-month Net Debt is ($15.9B), based on the financial report for Dec 31, 2024 (Q4 2024).

2) What is Regeneron Pharmaceuticals, Inc.'s Net Debt growth rate?

Over the last year, Regeneron Pharmaceuticals, Inc.'s Net Debt growth was 95.6%. The average annual Net Debt growth rates for Regeneron Pharmaceuticals, Inc. have been 218.1% over the past three years, 22.6% over the past five years.

3) Is Regeneron Pharmaceuticals, Inc.'s Net Debt growth rate Good?

Over the last year, Regeneron Pharmaceuticals, Inc.'s Net Debt growth was 95.6%, which is higher than industry growth of (0.1%). It indicates that Regeneron Pharmaceuticals, Inc.'s Net Debt growth is Bad.

4) How does Regeneron Pharmaceuticals, Inc.'s Net Debt growth rate compare to its peers?

Over the last year, Regeneron Pharmaceuticals, Inc.'s Net Debt growth was 95.6%, which is higher than peer median growth of (33.1%). The list of peers includes NVO, SMMT, RPRX, ALNY, BGNE, INCY, UTHR, VRTX, BNTX, ARGX etc.